非酒精性脂肪肝和减重  

Nonalcoholic Fatty Liver Disease and Weight Loss

作　　者：平凡[1] 李玉秀[1] PING Fan;LI Yuxiu(Key Laboratory of Endocrinology of Ministry of Health,Department of Endocrinology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科卫生部内分泌重点实验室,北京100730

出　　处：《中国医学科学院学报》2018年第5期597-602,共6页Acta Academiae Medicinae Sinicae

摘　　要：非酒精性脂肪肝病(NAFLD)是指排除了其他已知原因(如大量的酒精摄入或肝炎病毒感染)的肝脏脂肪样变,在全球范围内已成为广泛的危害健康的慢性疾病且流行趋势进行性扩大。肥胖主要通过肝脏的胰岛素抵抗导致三酰甘油在肝脏的沉积,从而促进NAFLD的发生发展。减轻体质量是唯一有充分证据显示对NAFLD安全有效的方法。生活方式干预在NAFLD的治疗中有着基石地位,但大多数肥胖的患者仅通过生活方式干预很难达到并维持理想体质量的状态。减重药物中的胰高血糖素样肽类似物及代谢手术都是治疗NAFLD较有前景的方法。Nonalcoholic fatty liver disease(NAFLD)refers to hepatic steatosis without other known causes such as alcohol abuse or hepatic virus infection.NAFLD has become a chronic disease worldwide,and its prevalence is constantly growing.Hepatic insulin resistance caused by obesity results in the deposition of triglycerides in the liver,promoting the occurrence and development of NAFLD.Weight loss is the only safe and effective method for NAFLD.Lifestyle intervention plays a cornerstone role in treating NAFLD;however,most patients can not achieve and maintain the ideal body weight by lifestyle intervention alone.Glucagon-like peptide-1 receptor agonist and metabolic surgery are promising treatments for NAFLD.

关 键 词：肥胖 非酒精性脂肪肝 胰高血糖素样肽-1类似物 代谢手术 

分 类 号：R589[医药卫生—内分泌]